AtriCure reported second-quarter fiscal 2026 results that beat consensus estimates, with revenue of $153.6 million and adjusted earnings per share of $0.18. Revenue exceeded expectations by $1.79 million and adjusted EPS surpassed forecasts by $0.16, an 800% beat. The company swung to a net income of $9 million from a net loss of $6.2 million a year earlier, while adjusted EBITDA reached $27 million. Gross margin expanded 270 basis points to 77.2%, driven by product innovation, geographic mix, and efficiencies. Management raised full-year revenue guidance to $602 million to $610 million and adjusted EBITDA guidance to $85 million to $89 million, with EPS expected between $0.05 and $0.13.
AtriCure IncAtriCure beat Q2 estimates, swung to net income, raised guidance, and expanded margins.
AgomAb Therapeutics NV American Depositary Shares
Edwards Lifesciences Corp
Medtronic PLC